title: Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study.
abstract: OBJECTIVE
  To assess the role of dutasteride in preventing clinical progression of benign prostatic hyperplasia in asymptomatic men with larger prostates.
  
  
  METHODS
  Post hoc analysis of four year, double blind Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study
  
  
  METHODS
  1617 men randomised to dutasteride or placebo with a prostate size >40 mL and baseline International Prostate Symptom Score (IPSS) <8. Subjects who took medications for benign prostatic hyperplasia were excluded at study entry.
  
  
  METHODS
  Placebo or dutasteride 0.5 mg daily.
  
  
  METHODS
  Comparison of risk of clinical progression of benign prostatic hyperplasia at four years (defined as a ≥ 4 point worsening on IPSS, acute urinary retention, urinary tract infection, or surgery related to benign prostatic hyperplasia).
  
  
  RESULTS
  825 participants took placebo, 792 took dutasteride. A total of 464 (29%) experienced clinical progression benign prostatic hyperplasia, 297(36%) taking placebo, 167 (21%) taking dutasteride (P<0.001). The relative risk reduction was 41% and the absolute risk reduction 15%, with a number needed to treat (NNT) of 7. Among men who had acute urinary retention and surgery related to benign prostatic hyperplasia, the absolute risk reduction for dutasteride was 6.0% and 3.8%, respectively. On multivariable regression analysis adjusting for covariates, dutasteride significantly reduced clinical progression of benign prostatic hyperplasia with an odds ratio of 0.47 (95% CI 0.37 to 0.59, P<0.001). Analysis of time to first event yielded a hazard ratio of 0.673 (P<0.001) for those taking dutasteride. Sexual adverse events were most common and similar to prior reports.
  
  
  CONCLUSIONS
  Further prospective studies may be warranted to demonstrate generalisability of these results.
  
  
  CONCLUSIONS
  This study is the first to explore the benefit of treating asymptomatic or mildly symptomatic men with an enlarged prostate. Dutasteride significantly decreased the incidence of benign prostatic hyperplasia clinical progression.
authors.affiliation: Division of Urology, Department of Surgery, University of Toronto, University Health Network, 610 University Avenue, 3-130, Toronto, Ontario, Canada M5G 2M9.
authors.forename: Paul
authors.initials: P
authors.lastname: Toren
authors.forename: David
authors.initials: D
authors.lastname: Margel
authors.forename: Girish
authors.initials: G
authors.lastname: Kulkarni
authors.forename: Antonio
authors.initials: A
authors.lastname: Finelli
authors.forename: Alexandre
authors.initials: A
authors.lastname: Zlotta
authors.forename: Neil
authors.initials: N
authors.lastname: Fleshner
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D000368:Aged; D058070:Asymptomatic Diseases; D001378:Azasteroids / Q000008:administration & dosage / Q000009:adverse effects; D018450:Disease Progression; D004311:Double-Blind Method; D016903:Drug Monitoring / Q000379:methods; D000068538:Dutasteride; D007172:Erectile Dysfunction / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D011467:Prostate / Q000187:drug effects / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D012044:Regression Analysis; D018570:Risk Assessment; D016896:Treatment Outcome; D016055:Urinary Retention / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D014552:Urinary Tract Infections / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*
chemical_list: D058891:5-alpha Reductase Inhibitors; D001378:Azasteroids; D017430:Prostate-Specific Antigen; D000068538:Dutasteride